Clofazimine: An old drug for never-ending diseases

Niccolò Riccardi, Andrea Giacomelli, Diana Canetti, Agnese Comelli, Enrica Intini, Giovanni Gaiera, Mama M. Diaw, Zarir Udwadia, Giorgio Besozzi, Luigi Codecasa, Antonio Di Biagio

Research output: Contribution to journalReview articlepeer-review


Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential in vitro mechanism of actions, to the spectrum of side effects and potential drug-drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis.

Original languageEnglish
Pages (from-to)557-566
Number of pages10
JournalFuture Microbiology
Issue number7
Publication statusPublished - May 1 2020


  • clofazimine
  • leprosy
  • MDR-TB
  • NTM
  • XDR-TB

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Clofazimine: An old drug for never-ending diseases'. Together they form a unique fingerprint.

Cite this